Form 4: Elicio Therapeutics Executive Acquires Stock Options

Peter DeMuth, Chief Scientific Officer of Elicio Therapeutics, acquired 29,800 stock options on September 30, 2024, at an exercise price of $5.03.

Summary

• Peter DeMuth, the Chief Scientific Officer of Elicio Therapeutics, acquired 29,800 stock options on September 30, 2024.
• The exercise price for these options is $5.03.
• 50% of the options vest on September 30, 2025, and the remaining 50% vest on September 30, 2026, contingent upon continued service to the company.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, suggesting a positive outlook on the company's ability to attract and retain talent. The sentiment is neutral to slightly positive.

Positives

• The acquisition of stock options by a key executive demonstrates alignment with the company's future success.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded biotechnology companies.
• The vesting schedule of 50% per year is fairly typical, aligning with industry norms for incentivizing long-term commitment.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• The grant incentivizes the Chief Scientific Officer to contribute to the company's long-term success, benefiting shareholders.

Key Dates